Cite
Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer
MLA
Maria Buxó, et al. “Cytokeratin 5/6 Fingerprinting in HER2-Positive Tumors Identifies a Poor Prognosis and Trastuzumab-Resistant Basal-HER2 Subtype of Breast Cancer.” Oncotarget, vol. 6, no. 9, Dec. 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0e7f6d155e248a274f37d4d8ed547412&authtype=sso&custid=ns315887.
APA
Maria Buxó, Joan Dorca, Francesc Tuca-Rodríguez, Miguel Alonso Ruano, Javier A. Menendez, Ramon Colomer, Eugeni López-Bonet, & Begoña Martin-Castillo. (2014). Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer. Oncotarget, 6(9).
Chicago
Maria Buxó, Joan Dorca, Francesc Tuca-Rodríguez, Miguel Alonso Ruano, Javier A. Menendez, Ramon Colomer, Eugeni López-Bonet, and Begoña Martin-Castillo. 2014. “Cytokeratin 5/6 Fingerprinting in HER2-Positive Tumors Identifies a Poor Prognosis and Trastuzumab-Resistant Basal-HER2 Subtype of Breast Cancer.” Oncotarget 6 (9). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0e7f6d155e248a274f37d4d8ed547412&authtype=sso&custid=ns315887.